Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings

Current Opinion in HIV and AIDS

Volumn 5, Issue 1, 2010, Pages 18-26

  Lawn, Stephen D ^a,b   Harries, Anthony D ^b,c   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Antiretroviral; Death; HIV; Low income; Morbidity; Mortality; Resource limited

Indexed keywords

AMPHOTERICIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CORTICOSTEROID; COTRIMOXAZOLE; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; ISONIAZID; NEVIRAPINE; PLACEBO; RIFAMPICIN; STAVUDINE;

AFRICA; AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CENTRAL AMERICA; CHRONIC DIARRHEA; CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; DEVELOPED COUNTRY; DRUG MEGADOSE; EARLY DIAGNOSIS; ECONOMIC ASPECT; ESCHERICHIA COLI; FOLLICULITIS; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOGENESIS; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; KAPOSI SARCOMA; MOLLUSCUM CONTAGIOSUM; MORBIDITY; MORTALITY; NEOPLASM; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SALMONELLA; SCREENING; SEPSIS; SKIN ABSCESS; SOUTH AND CENTRAL AMERICA; SOUTHEAST ASIA; TUBERCULOSIS; VARICELLA ZOSTER VIRUS; VIRUS DIAGNOSIS; VIRUS IMMUNITY; WASTING SYNDROME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DEVELOPING COUNTRIES; HIV INFECTIONS; HIV-1; HUMANS; MENINGITIS, CRYPTOCOCCAL; MORBIDITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 74349097845     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328333850f     Document Type: Review

References (77)

1. UNAIDS. 2008 Report on the global AIDS epidemic. Geneva: UNAIDS; 2008. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/ 2008/2008-Global-report.asp.
2. World Health Organization. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2008. Geneva: World Health Organization. http://www.who.int/entity/hiv/pub/towards-universal- access-report-2008.pdf. 2008.
3. Souteyrand Y, Akwara P, Warner Smith M, et al. Scaling up access to antiretroviral therapy (ART) in low-income and middle-income countries: global and regional progress in 2008. Abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; July 2009. International AIDS Society. Abstract WELBD105.
4. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
5. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
6. Tuboi SH, Schechter M, McGowan CC, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2009; 51:615-623.
7. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 2009; 4:e5790.
8. Chasombat S, McConnell MS, Siangphoe U, et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 2009; 50:506-512.
9. Ferradini L, Laureillard D, Prak N, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007; 21:2293-2301.
10. Keiser O, Orrell C, Egger M, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5:e148.
11. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335-342.
12. Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717-1725.
13. Srasuebkul P, Lim PL, Lee MP, et al. Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from theTREATAsiaHIVobservationaldatabase. ClinInfect Dis2009;48:940-950.
14. Chen SC, Yu JK, Harries AD, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health 2008; 13:513-519.
15. Cornell M, Myer L, Kaplan R, et al. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health 2009; 14:722-731.
16. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008; 86:559-567.
17. Boyer S, Marcellin F, Ongolo-Zogo P, et al. Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ 2009; 87:279-287.
18. Madec Y, Laureillard D, Pinoges L, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 2007; 21:351-359.
19. Castelnuovo B, Manabe YC, Kiragga A, et al. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009; 49:965-972.
20. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005; 353:2325-2334.
21. Dillingham RA, Pinkerton R, Leger P, et al. High early mortality in patients with chronic acquired immunodeficiency syndrome diarrhea initiating antiretroviral therapy in Haiti: a case-control study. Am J Trop Med Hyg 2009; 80:1060-1064.
22. Kumarasamy N, Venkatesh KK, Devaleenol B, et al. Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India. Int J Infect Dis 2009. [Epub ahead of print]
23. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612.
24. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21:713-719.
25. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009; 48:829-831.
26. Yu JK, Bong CN, Chen SC, et al. Outcomes in HIV-infected patients who develop tuberculosis after starting antiretroviral treatment in Malawi. Int J Tuberc Lung Dis 2008; 12:692-694.
27. Westreich D, MacPhail P, Van RA, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS 2009; 23:707-715.
28. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20:2355-2360.
29. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
30. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993; 7:1569-1579.
31. Lawn SD, Edwards DJ, Wood R. Reducing the burden of tuberculosis during the initial months of antiretroviral therapy in resource-limited settings. Clin Infect Dis (in press).
32. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
33. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009; 48:e96-e107.
34. Martin J, Laker M, Clutter D, et al. Kaposi's sarcoma-associated IRIS in Africa: initial findings from a prospective evaluation. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 2009. Abstract 31.
35. Lawn SD, Bekker LG, Myer L, et al. Cryptococcal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005; 19:2050-2052.
36. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviralexperienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80.
37. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
38. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694-1701.
39. Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856-862.
40. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21:2483-2491.
41. Paiardini M, Frank I, Pandrea I, et al. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev 2008; 10:36-46.
42. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-2116.
43. Bonnet MM, Pinoges LL, Varaine FF, et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 2006; 20:1275-1279.
44. Brinkhof MW, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45:1518-1521.
45. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and 'unmasking' of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177:680-685.
46. Lawn SD, Edwards SD, Kranzer K, et al. Urine lipoarabinomannan assay for tuberculosis screening prior to ART: diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23:1875-1880.
47. Murdoch DM, Venter WD, Feldman C, Van RA. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601-610.
48. Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009; 48:667-676.
49. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006; 368:1254-1259.
50. WHO/UNAIDS. Guidance on provider-initiated HIV testing and counselling in health facilities. Joint United Nations Programme on HIV/AIDS. 2007. Geneva, Switzerland: World Health Organization. http://www.who.int/hiv/pub/ guidelines/9789241595568-en.pdf.
51. April MD, Walensky RP, Chang Y, et al. HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr 2009; 51:310-316.
52. Bassett IV, Wang B, Chetty S, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009; 51:135-139.
53. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. Geneva: World Health Organization. http://www.who.int/hiv/pub/ guidelines/artadultguidelines.pdf. Accessed 14 August 2009
54. Badri M, Bekker LG, Orrell C, et al. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS 2004; 18:1159-1168.
55. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144.
56. Fitzgerald D. Early versus delayed ART: results from Haiti. Abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; July 2009. International AIDS Society. Abstract WESY201.
57. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIVrelated infections among children, adolescents and adults. Recommendations for a public health approach. 2006. http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf. Accessed 14th August 2009
58. Nunn AJ, Mwaba P, Chintu C, et al. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 2008; 337:a257.
59. World Health Organization. WHO three 'I's meeting. Report of a joint WHO HIV/AIDS and TB Department Meeting; 2008. Geneva: WHO. http:// www.who.int/hiv/pub/meetingreports/WHO-3Is-meeting-report.pdf.
60. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9:173-184.
61. Bassett I, Chetty S, Wang B, et al. Intensive TB screening for HIV-infected patients ready to start ART in Durban, South Africa: limitations of WHO guidelines. Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 2009. Abstract 779.
62. Dawson R, Masuka P, Edwards DJ, et al. Chest radiograph reading and reporting system (CRRS): evaluation for TB screening in advanced HIV patients. Int J Tuberc Lung Dis 2009; in press.
63. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-1580.
64. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement June 2008. www.who.int/entity/tb/dots/laboratory/lpa-policy. pdf.
65. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004:CD000171.
66. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631-636.
67. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIVinfected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441-1448.
68. Westreich DJ, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009; 48:1617-1623.
69. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007; 12:929-935.
70. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009; 13:6-16.
71. Boulle A, Van CG, Cohen K, et al. Outcomes of nevirapine-and efavirenzbased antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530-539.
72. Abdool Karim S, Naidoo K, Grobler A, et al. Initiating ART during TB treatment significantly increases survival: results of a randomized controlled trial in TB/ HIV-co-infected patients in South Africa. Programme and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal, Canada; February 2009. Abstract 36a.
73. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomised placebo-controlled trial of prednisone for TB IRIS. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 2009. Abstract 34.
74. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47:123-130.
75. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008; 47:1556-1561.
76. Zachariah R, Harries AD, Manzi M, et al. Acceptance of antiretroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. PLoS ONE 2006; 1:e121.
77. Zachariah R, Teck R, Buhendwa L, et al. Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. Trans R Soc Trop Med Hyg 2007; 101:79-84. (Pubitemid 44760916)